The Clinical Core operates as the unit of the Oregon Alzheimer's Disease Center (OADC) with responsibility for identification, recruitment, characterization, and follow-up of populations of well-characterized subjects for clinical research. In keeping with the OADC focus, the Clinical Core is organized to optimize research, leading to better defining normal aging and the transitions to mild cognitive impairment (MCI) and early dementia. In order to fulfill this mission, the Clinical Core completes systematic assessments resulting in standardized diagnoses of the research cohorts, which are then entered into the relational database of the OADC. Many types of data are collected in order to be responsive to current and anticipated needs of the research community: clinical histories, neurological examinations, MRI brain images, neuropsychological and behavioral assessments, and laboratory data. The Clinical Core works closely with the other cores of the Center to ensure tissue donations (Neuropathology Core), characterization of biomarkers and genetic associations (Biomarkers and Genetics Core) and smooth transfer, entry, storage and retrieval for analysis of the data (Data Management and Statistics Core). The Clinical Core faculty acts as an important knowledge resource, participating in Education and Information Core educational activities and programs. The Clinical Core is dedicated to on-going evaluation of its identified cohorts and to ensuring that subjects are not lost to follow-up. Several groups form a particular focus of the Clinical Core: 1) early Alzheimer's disease and related dementias;2) non-cognitively impaired or MCI elderly at high risk for developing dementia, emphasizing the oldest old;and 3) subjects reflecting social and racial diversity (African American and isolated rural populations) through the Satellite program. These subject groups and the research resources they create are used for a wide range of studies, including the natural history of aging without cognitive impairment, detection of cognitive decline with unobtrusive in-home monitoring technologies, the genetics of incipient dementia, biomarkers of underlying disease, and novel treatment or prevention regimens for cognitive decline. Implicit in this core is a fundamental commitment to research collaboration both within our local pool of talented investigators, as well as with our colleagues among the larger community of scientists at other ADC's and other relevant research institutions.

Public Health Relevance

The OADC Clinical Core provides the key research faculty, staff, and subject volunteers for the complete characterization of subjects involved in research focused on advancing the clinical science of detection, diagnosis and treatment of early cognitive decline. This ready clinical resource and infrastructure are intended to facilitate research in a manner that is widely shared, collaborative and responsive to the rapid development of knowledge about early dementia or the years before symptoms fully develop.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
2P30AG008017-21
Application #
8013418
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J1))
Project Start
Project End
Budget Start
2010-05-15
Budget End
2011-03-31
Support Year
21
Fiscal Year
2010
Total Cost
$115,405
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Wardzala, Casia; Murchison, Charles; Loftis, Jennifer M et al. (2018) Sex differences in the association of alcohol with cognitive decline and brain pathology in a cohort of octogenarians. Psychopharmacology (Berl) 235:761-770
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416

Showing the most recent 10 out of 482 publications